Aim: The aim of this study is to compare the traditional clinical and laboratory
parameters used for the diagnosis and activity of sarcoidosis with ⁶⁸Ga citrate PET/CT
and ¹⁸F-FDG PET/CT findings.
Material and Method: 19 ⁶⁸Ga citrate PET/CT scans and 20 ⁶⁸Ga citrate
PET/CT and ¹⁸F-FDG PET/CT scans of both patients were included in the study.
Demographic features of the cases, clinical findings, chest X-ray, Thorax CT,
respiratory function tests, laboratory results, bronchoscopic and extrapulmonary organ
biopsies,
⁶⁸Ga citrate PET/CT and ¹⁸F-FDG PET/CT scan results retrospectively. The
obtained data were uploaded to computer systems. Analysis was performed using
statistical methods.
Conclusion: A statistically significant difference was found between ⁶⁸Ga
Citrate PET/CT result and acceptance of active sarcoidosis (p=0.001), acceptance of
clinical sarcoidosis (p=0.029), and probability of sarcoidosis (p=0.020). There was no
statistically significant difference between the ¹⁸F-FDG PET/CT and ⁶⁸Ga Citrate
PET/CT results of patients who were accepted as clinical sarcoidosis (p=0.1000).
Extrathoracic involvement was detected in %44,4 of 18 patients with active sarcoidosis
in ⁶⁸Ga citrate PET/CT. The cost advantage of ⁶⁸Ga Citrate PET/CT has been
demonstrated.
Results: The success of ⁶⁸Ga citrate PET/CT has been proven in the diagnosis
of sarcoidosis, activation and detection of extrathoracic involvement and
determination of biopsy sites. No significant difference was found in the comparison
with ¹⁸F-FDG PET/CT